Trial Scale
Cross-source consensus on Trial Scale from 1 sources and 4 claims.
1 sources · 4 claims
Evidence quality
Highlighted claims
- At the time of writing, BALANCE+ had expanded to 37 sites in four countries. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
- At the time of writing, BALANCE+ had enrolled more than 1,300 patients. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
- At a 37-site scale, projected enrolment is about 2,215 patients per year. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
- If the trial expands to the size of the parent BALANCE trial, annual enrolment could reach about 5,464 patients. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+